ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kohri, K
Right arrow Articles by Nagai, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kohri, K
Right arrow Articles by Nagai, A
Eur Respir J 2000; 15: 62-67
Copyright © ERS Journals Ltd 2000


Original Articles

Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages

K Kohri, J Tamaoki, M Kondo, K Aoshiba, E Tagaya, and A Nagai

There is evidence that macrolide antibiotics are effective in the treatment of chronic airway inflammatory diseases, probably through actions other than their antibacterial properties. In order to determine whether macrolides affect the nitric oxide-generating system in the respiratory tract, rat pulmonary alveolar macrophages (PAMs) were studied in vitro. The release of NO was assessed by direct measurement with a specific amperometric sensor for this molecule, and the expression of type II NO synthase (NOS) messenger ribonucleic acid (mRNA) was determined by Northern blotting. Incubation of PAMs with lipopolysaccharide from Escherichia coli and recombinant human interferon-gamma caused release of NO, which was accompanied by induction of type II NOS mRNA. The release of NO was reduced by coincubation of cells with the macrolides erythromycin, clarithromycin and josamycin in a concentration-dependent manner, the maximal inhibition being 73+/-10, 81+/-6 and 84+/-9%, respectively, but was not altered by amoxycillin or cefaclor. These macrolides likewise inhibited the induction of type II NOS mRNA, whereas no inhibitory effects were observed with amoxycillin or cefaclor. These results suggest that macrolide antibiotics specifically inhibit type II NO synthase gene expression and consequently reduce NO production by rat pulmonary alveolar macrophages, which might result in attenuation of airway inflammation.


This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
K. Lotter, K. Hocherl, M. Bucher, and F. Kees
In vivo efficacy of telithromycin on cytokine and nitric oxide formation in lipopolysaccharide-induced acute systemic inflammation in mice
J. Antimicrob. Chemother., September 1, 2006; 58(3): 615 - 621.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
K.W. Southern and P.M. Barker
Azithromycin for cystic fibrosis
Eur. Respir. J., November 1, 2004; 24(5): 834 - 838.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H. W. Chu, M. Kraft, M. D. Rex, and R. J. Martin
Evaluation of Blood Vessels and Edema in the Airways of Asthma Patients : Regulation With Clarithromycin Treatment
Chest, August 1, 2001; 120(2): 416 - 422.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the European Respiratory Society.